Vigil Neuroscience (NASDAQ:VIGL – Get Rating) and Revolution Medicines (NASDAQ:RVMD – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.
Earnings & Valuation
This table compares Vigil Neuroscience and Revolution Medicines’ revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vigil Neuroscience | N/A | N/A | -$68.31 million | ($2.19) | -4.57 |
| Revolution Medicines | $35.38 million | 52.59 | -$248.71 million | ($3.10) | -6.63 |
Vigil Neuroscience has higher earnings, but lower revenue than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Vigil Neuroscience, indicating that it is currently the more affordable of the two stocks.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Vigil Neuroscience | N/A | -38.38% | -36.59% |
| Revolution Medicines | -702.95% | -41.17% | -33.68% |
Risk and Volatility
Vigil Neuroscience has a beta of 3.41, meaning that its stock price is 241% more volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings for Vigil Neuroscience and Revolution Medicines, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vigil Neuroscience | 0 | 1 | 4 | 0 | 2.80 |
| Revolution Medicines | 0 | 2 | 6 | 0 | 2.75 |
Vigil Neuroscience presently has a consensus price target of $18.80, suggesting a potential upside of 87.81%. Revolution Medicines has a consensus price target of $32.25, suggesting a potential upside of 56.86%. Given Vigil Neuroscience’s stronger consensus rating and higher possible upside, research analysts clearly believe Vigil Neuroscience is more favorable than Revolution Medicines.
Insider & Institutional Ownership
88.9% of Vigil Neuroscience shares are held by institutional investors. 46.6% of Vigil Neuroscience shares are held by company insiders. Comparatively, 18.8% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Vigil Neuroscience beats Revolution Medicines on 10 of the 13 factors compared between the two stocks.
About Vigil Neuroscience
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts. Vigil Neuroscience, Inc. operates as a subsidiary of Amgen Inc.
About Revolution Medicines
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Receive News & Ratings for Vigil Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vigil Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
